A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS
Publication
, Conference
Brown, D; Bacha, J; Wagner, L; Leggas, M; Kanekal, S; Lopez, L; Sankar, N
Published in: Neuro Oncology
2020
Duke Scholars
Published In
Neuro Oncology
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2020
Volume
22
Start / End Page
60 / 60
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Brown, D., Bacha, J., Wagner, L., Leggas, M., Kanekal, S., Lopez, L., & Sankar, N. (2020). A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS. In Neuro Oncology (Vol. 22, pp. 60–60).
Brown, Dennis, Jeffrey Bacha, Lars Wagner, Markos Leggas, Sarath Kanekal, Lorena Lopez, and Neil Sankar. “A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS.” In Neuro Oncology, 22:60–60, 2020.
Brown D, Bacha J, Wagner L, Leggas M, Kanekal S, Lopez L, et al. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS. In: Neuro Oncology. 2020. p. 60–60.
Brown, Dennis, et al. “A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS.” Neuro Oncology, vol. 22, 2020, pp. 60–60.
Brown D, Bacha J, Wagner L, Leggas M, Kanekal S, Lopez L, Sankar N. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS. Neuro Oncology. 2020. p. 60–60.
Published In
Neuro Oncology
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2020
Volume
22
Start / End Page
60 / 60
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences